Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.
Blood Adv. 2022.
PMID: 35020818
Free PMC article.
No abstract available.